Abstract：
Despite controversies, no study has systematically summarized findings from earlier studies on the effect of berberine (BBR)-silymarin on liver enzymes. Therefore, the current systematic review and meta-analysis aimed to investigate the effect of berberis aristate and Silybum marianum on alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in adults.
Relevant studies, published up to June 2021, were searched through PubMed/Medline, Scopus, ISI Web of Science, EMBASE and Google Scholar. The mean differences and standard deviations were pooled using a random-effects model. The studies\' quality was evaluated using the Cochrane Risk of Bias Tool.
Out of 80 citations, 5 trials that enrolled 549 participants were included. Berberis aristate and Silybum marianum resulted in no statistically significant change in ALT (weighted mean differences (WMD): -0.39 mg/dl; 95% CI: -1.67 to 0.89, P = 0.55), and AST (WMD: -0.44 mg/dl; 95% CI: -2.02 to 1.14, P = 0.58).
We did not find any significant reduction in liver enzymes following BBR-silymarin consumption in adults. Further clinical trials with high quality according to the challenges mentioned seem to be helpful to use BBR-silymarin as a supplement for improving liver function.
Relevant studies, published up to June 2021, were searched through PubMed/Medline, Scopus, ISI Web of Science, EMBASE and Google Scholar. The mean differences and standard deviations were pooled using a random-effects model. The studies\' quality was evaluated using the Cochrane Risk of Bias Tool.
Out of 80 citations, 5 trials that enrolled 549 participants were included. Berberis aristate and Silybum marianum resulted in no statistically significant change in ALT (weighted mean differences (WMD): -0.39 mg/dl; 95% CI: -1.67 to 0.89, P = 0.55), and AST (WMD: -0.44 mg/dl; 95% CI: -2.02 to 1.14, P = 0.58).
We did not find any significant reduction in liver enzymes following BBR-silymarin consumption in adults. Further clinical trials with high quality according to the challenges mentioned seem to be helpful to use BBR-silymarin as a supplement for improving liver function.
摘要：
尽管存在争议,没有研究系统地总结了早期关于小檗碱（BBR）-水飞蓟素对肝酶的影响的研究结果。因此,本系统综述和荟萃分析旨在研究小檗和水飞蓟对成人丙氨酸转氨酶(ALT)和天冬氨酸转氨酶(AST)的影响.
相关研究，截至2021年6月发布，通过PubMed/Medline搜索，Scopus,ISIWebofScience,EMBASE和谷歌学者。使用随机效应模型汇集平均值差异和标准偏差。使用Cochrane偏差风险工具评估研究质量。
在80篇引文中，纳入549名参与者的5项试验。小檗碱和水飞蓟菌导致ALT无统计学意义的变化（加权平均差异（WMD）：-0.39mg/dl;95％CI：-1.67至0.89，P=0.55），和AST（WMD：-0.44mg/dl；95%CI：-2.02至1.14，P=0.58）。
我们没有发现成人食用BBR-水飞蓟素后肝酶有任何显著降低。根据提到的挑战，高质量的进一步临床试验似乎有助于使用BBR-水飞蓟素作为改善肝功能的补充。
相关研究，截至2021年6月发布，通过PubMed/Medline搜索，Scopus,ISIWebofScience,EMBASE和谷歌学者。使用随机效应模型汇集平均值差异和标准偏差。使用Cochrane偏差风险工具评估研究质量。
在80篇引文中，纳入549名参与者的5项试验。小檗碱和水飞蓟菌导致ALT无统计学意义的变化（加权平均差异（WMD）：-0.39mg/dl;95％CI：-1.67至0.89，P=0.55），和AST（WMD：-0.44mg/dl；95%CI：-2.02至1.14，P=0.58）。
我们没有发现成人食用BBR-水飞蓟素后肝酶有任何显著降低。根据提到的挑战，高质量的进一步临床试验似乎有助于使用BBR-水飞蓟素作为改善肝功能的补充。
